ArkBiopharmaceutical

ArkBiopharmaceutical is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class and best-in-class therapies for viral infections and respiratory diseases. Headquartered in China, the company is most notable for its lead asset, AK0529, a potent small-molecule inhibitor of the Respiratory Syncytial Virus (RSV) fusion protein, which has successfully completed Phase 3 trials in pediatric patients. ArkBio's pipeline also includes candidates for human parainfluenza virus (HPIV) and chronic obstructive pulmonary disease (COPD), utilizing both small molecule and antibody modalities. The company aims to address significant unmet medical needs in global pediatric and adult populations through its integrated R&D platform and strategic collaborations. With a strong leadership team and backing from prominent global investors, ArkBio is positioned as a leader in the respiratory antiviral space in Asia.